Why Vaccination is Critically Important in Chronic Lung Diseases
Chronic airway diseases, such as bronchial asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis, represent a major global public health challenge. They are frequently accompanied by recurrent exacerbations, require hospitalization, and increase mortality risk [1]. Respiratory infections are one of the primary causes of these exacerbations, leading to worsened lung function and a reduced quality of life.
This is precisely why preventative strategies, especially vaccination, play a key role in managing these conditions. The goal of vaccination is to reduce the frequency of infection-driven exacerbations, stabilize lung function, and improve overall outcomes for patients [1]. Adults with comorbid conditions, such as asthma and COPD, are considered to be at an increased risk of developing invasive diseases, many of which can be prevented through routine immunization [2].
Key Vaccines for Patients with Chronic Respiratory Diseases
Scientific societies recommend vaccination against a range of major respiratory pathogens that pose a serious threat to individuals with chronic lung diseases [1].
Influenza Vaccination
Influenza is not only a respiratory infection but also a significant trigger of acute cardiovascular events [7]. Influenza and pneumococcal infections are considered potential risk factors for the development of adverse cardiovascular events, especially in high-risk patients [3].
Influenza vaccination in patients with pre-existing cardiovascular disease (CVD) can be a cost-effective intervention to improve clinical outcomes [3]. Studies have shown that influenza vaccination reduces mortality, the frequency of acute coronary syndromes, and hospitalizations in patients with coronary artery disease (CAD) and/or heart failure [3]. For adults with CVD, particularly elderly individuals and patients who have experienced a recent acute coronary syndrome or heart failure, influenza vaccination should be considered a low-risk, evidence-based component of cardiovascular prevention rather than merely protection against respiratory illness [7]. Randomized trials and meta-analyses confirm a reduction in major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality in high-risk secondary prevention groups, with particularly compelling evidence following myocardial infarction [7].
Pneumococcal Vaccination
Streptococcus pneumoniae is the primary etiological agent of bacterial pneumonia and is frequently involved in the development of bacterial meningitis, COPD exacerbations, and upper respiratory tract pathologies [4]. The high incidence, mortality rate, and emergence of antibiotic-resistant strains underscore the importance of an effective vaccination strategy against this bacterium [4].
Although studies on pneumococcal vaccination and its impact on cardiovascular events are fewer than those on influenza, cardiology societies also encourage its use [3].
Respiratory Syncytial Virus (RSV) Vaccination
Respiratory syncytial virus (RSV) causes significant morbidity in older adults, particularly those suffering from cardiovascular disease. RSV infection can trigger severe lower respiratory tract illness, hospitalization, functional decline, and cardiovascular destabilization [6]. Acute cardiac events frequently occur during RSV-related hospitalizations, and cardiovascular risk may persist even after the infection has resolved [6].
Clinical trials of the RSV vaccine initially reported a higher incidence of atrial fibrillation in the vaccination groups compared to control groups. However, a large population-based study demonstrated that the RSV vaccine was not associated with an increased risk of new-onset or recurrent atrial fibrillation within 1–42 days post-vaccination, compared to influenza or tetanus, diphtheria, and pertussis (Tdap) vaccines [5]. This provides vital data for assessing vaccine safety.
Other Important Vaccines
- SARS-CoV-2 (COVID-19): COVID-19 vaccination is also recommended for individuals with chronic respiratory diseases [1].
- Varicella-Zoster Virus (VZV): VZV vaccination is likewise included in the guidelines for this patient group [1].
Vaccination in Specific Chronic Lung Diseases
Vaccines have proven effective in minimizing exacerbations and improving outcomes in patients with asthma, COPD, and bronchiectasis [1]. For adults with asthma and COPD, vaccination is an essential part of the disease management strategy [2]. This helps not only to prevent infections but also to stabilize lung function, reducing the need for hospitalization and improving overall health status.
Special Populations: Vaccination of People with HIV
Vaccination recommendations for people with HIV differ from those for the general population. This is due to a potentially diminished immune response and an increased risk of developing infections or experiencing a more severe disease course [8]. People with HIV suffer from persistent immune dysfunction characterized by chronic immune activation and heightened susceptibility to certain infections [8].
Newer vaccines for the prevention of invasive pneumococcal diseases, respiratory syncytial virus (RSV), COVID-19, mpox, and hepatitis B virus are available and recommended for people with HIV [8]. To optimize the potential of vaccines in reducing infections and related malignancies in people with HIV, strategies aimed at improving vaccine immune responses and reducing vaccine hesitancy are necessary [8].
Conclusion
Vaccination is a cornerstone in the prevention and management of chronic airway diseases. It not only protects against infections that trigger exacerbations but also contributes to improved cardiovascular outcomes, which is particularly important for this vulnerable patient group. Regularly updated guidelines and the emergence of new vaccines underscore the dynamic nature of this field and the importance of a personalized approach for every patient.
Sources
- Vaccination Strategies in Respiratory Diseases: Recommendation from AIPO-ITS/ETS, SIMIT, SIP/IRS, and SItI. (Respiration; international review of thoracic diseases, 2025)
- Vaccination of adults with asthma and COPD. (Allergy, 2011)
- Beneficial impact of vaccination on cardiovascular events: myocardial infarction, stroke, heart failure. (Cardiology, 2018)
- The role of pneumococcal vaccine. (Pulmonary pharmacology & therapeutics, 2008)
- Atrial fibrillation following respiratory syncytial virus vaccination among older adults. (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026)
- Respiratory syncytial virus vaccination as a means to reduce cardiopulmonary and cardiovascular risk in adults with heart disease. (Journal of clinical medicine, 2026)
- Influenza vaccination as cardiovascular prevention in adults with heart disease. (Journal of clinical medicine, 2026)
- Updated vaccination recommendations for adults with HIV. (Current HIV/AIDS reports, 2025)
Disclaimer: The information provided in this article is for reference purposes only and cannot replace professional advice, diagnosis, or treatment provided by a qualified healthcare professional. Always consult your physician regarding health matters and before making any treatment or lifestyle modification decisions.